Author: admin

Shots: TeneoOne to receive $90M upfront and will take care of P-I trial for TNB-383B with its expected onset in H1’19. AbbVie to get exclusive WW rights to develop and commercialize Teneobio’s TNB-383B, with an option to acquire TeneoOne If AbbVie exercises option to acquire, TeneoOne will receive milestones on sales and regulatory approval of TNB-383B TNB-383B is a bispecific Ab used for targeting...

Read More

Shots: The P-III CLL14 Study involves assessing of Venclexta/Venclyxto + Gazyva/Gazyvaro vs Gazyva/Gazyvaro + chlorambucil in 432 patients with previously untreated CLL P-III CLL14 Study results: ORR (84.7% vs 71.3%); CR (49.5% vs 23.1%); patients receiving Venclexta/Venclyxto lived longer; disease progression @2yrs. (88.2% vs 64.1%); no new safety signals observed Venclexta/Venclyxto is a drug targeted for binding & inhibiting BCL-2 protein, further leads to apoptosis and has...

Read More

Shots: The agreement involves assessing safety, efficacy and tolerability of BeiGene's RAFi dimer, lifirafenib (BGB-283) and SpringWorks' MEKi (PD-0325901), in patients with advanced solid tumours BeiGene will look forward for onset of P-Ib trial for advanced solid tumours while SpringWorks will oversee fixed dosing formulation in trial The P-Ib trial is expected to initiate in Q1’19 while the costing and governance responsibilities of the trial will be...

Read More

Shots: The partial clinical hold follows P-III BELLINI trial (M14-031) study results assessing Venetoclax + bortezomib + dexamethasone vs PBO + bortezomib + dexamethasone in patients with 1L+ r/r MM due to a higher proportion of deaths in the experimental arm vs PBO arm The P-III BELLINI study results: observed death (21.1% vs 11.3%); Gr 3-5 toxicity (86.5% vs. 87.5%); SAEs (48.2% vs. 50.0%); incidence of infection...

Read More

Shots: Roche acquires Spark Therapeutics, in an all-stock transaction for $114.50 /share in cash, making the total deal value $4.3B. Spark to receive a premium of 122% based on its last day closing share price value i.e., 22Feb’19 The focus of the acquisition is to expand Roche’s footprints in genetic disorders incl. blindness, hemophilia, lysosomal storage disorders, and neurodegenerative diseases Spark Therapeutics’ portfolio includes SPK-8011...

Read More

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros...

Read More

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros...

Read More

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros...

Read More

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros...

Read More